JP5037349B2 - ＲＳＶ、ＰＩＶおよび他の呼吸器系ウイルスのＲＮＡｉ調節とその使用法 - Google Patents

ＲＳＶ、ＰＩＶおよび他の呼吸器系ウイルスのＲＮＡｉ調節とその使用法 Download PDF

Info

Publication number
JP5037349B2
JP5037349B2 JP2007538147A JP2007538147A JP5037349B2 JP 5037349 B2 JP5037349 B2 JP 5037349B2 JP 2007538147 A JP2007538147 A JP 2007538147A JP 2007538147 A JP2007538147 A JP 2007538147A JP 5037349 B2 JP5037349 B2 JP 5037349B2
Authority
JP
Japan
Prior art keywords
irna
sirna
rsv
drug
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007538147A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008517940A (ja
JP2008517940A5 (enExample
Inventor
バリク、セイレン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Alabama
Original Assignee
University of South Alabama
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of South Alabama filed Critical University of South Alabama
Publication of JP2008517940A publication Critical patent/JP2008517940A/ja
Publication of JP2008517940A5 publication Critical patent/JP2008517940A5/ja
Application granted granted Critical
Publication of JP5037349B2 publication Critical patent/JP5037349B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2007538147A 2004-10-22 2005-10-21 ＲＳＶ、ＰＩＶおよび他の呼吸器系ウイルスのＲＮＡｉ調節とその使用法 Expired - Fee Related JP5037349B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US62155204P 2004-10-22 2004-10-22
US60/621,552 2004-10-22
US11/151,976 2005-06-14
US11/151,893 2005-06-14
US11/151,893 US7592322B2 (en) 2004-10-22 2005-06-14 RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
US11/151,976 US20060089324A1 (en) 2004-10-22 2005-06-14 RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
PCT/US2005/038269 WO2006062596A2 (en) 2004-10-22 2005-10-21 RNAi MODULATION OF RSV, PIV AND OTHER RESPIRATORY VIRUSES AND USES THEREOF

Publications (3)

Publication Number Publication Date
JP2008517940A JP2008517940A (ja) 2008-05-29
JP2008517940A5 JP2008517940A5 (enExample) 2008-11-27
JP5037349B2 true JP5037349B2 (ja) 2012-09-26

Family

ID=36578352

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007538147A Expired - Fee Related JP5037349B2 (ja) 2004-10-22 2005-10-21 ＲＳＶ、ＰＩＶおよび他の呼吸器系ウイルスのＲＮＡｉ調節とその使用法

Country Status (12)

Country Link
US (2) US7592322B2 (enExample)
EP (1) EP1806968B1 (enExample)
JP (1) JP5037349B2 (enExample)
KR (1) KR101193825B1 (enExample)
CN (1) CN101087527B (enExample)
AU (1) AU2005314617B2 (enExample)
BR (1) BRPI0517286A (enExample)
CA (1) CA2584309A1 (enExample)
MX (1) MX2007004692A (enExample)
NO (1) NO20071953L (enExample)
RU (1) RU2494745C2 (enExample)
WO (1) WO2006062596A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1478656B1 (en) 2002-02-01 2009-09-16 Life Technologies Corporation Oligonucleotide compositions with enhanced efficiency
US20030166282A1 (en) 2002-02-01 2003-09-04 David Brown High potency siRNAS for reducing the expression of target genes
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
US8258288B2 (en) * 2002-02-20 2012-09-04 Sirna Therapeutics, Inc. RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
WO2006085987A2 (en) * 2004-07-09 2006-08-17 University Of Iowa Research Foundation Rna interference in respiratory epitheial cells
US7790878B2 (en) * 2004-10-22 2010-09-07 Alnylam Pharmaceuticals, Inc. RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
EA017847B1 (ru) * 2005-01-07 2013-03-29 Элнилэм Фармасьютикалз, Инк. Композиция для лечения респираторных синцитиальных вирусов
WO2008118013A2 (en) 2007-03-23 2008-10-02 To-Bbb Holding B.V. Targeted intracellular delivery of antiviral agents
JP2010527914A (ja) * 2007-04-26 2010-08-19 クォーク ファーマシューティカルズ インコーポレーティッド 呼吸器系への抑制性核酸分子の治療的送達
WO2009055445A2 (en) * 2007-10-22 2009-04-30 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
NZ585784A (en) * 2007-12-13 2012-09-28 Alnylam Pharmaceuticals Inc siRNAs for the treatment and prevention of respiratory syncytial virus (RSV) infection
AU2009273878A1 (en) * 2008-07-25 2010-01-28 Alnylam Pharmaceuticals, Inc. Enhancement of siRNA silencing activity using universal bases or mismatches in the sense strand
WO2010048590A1 (en) * 2008-10-23 2010-04-29 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of rsv infection using modified duplex rna molecules
CA2792469A1 (en) * 2010-03-08 2011-09-15 Novartis Ag Methods of testing for intracellular pathogens
AU2012223366B2 (en) * 2011-03-03 2017-02-23 Quark Pharmaceuticals, Inc. Oligonucleotide modulators of the toll-like receptor pathway
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
US8916352B2 (en) * 2011-04-08 2014-12-23 Bio-Rad Laboratories, Inc. PCR reaction mixtures with decreased non-specific activity
US11163898B2 (en) * 2013-09-11 2021-11-02 Mimecast Services Ltd. Sharing artifacts in permission-protected archives
EA201790551A1 (ru) 2014-09-07 2017-07-31 Селекта Байосайенсиз, Инк. Способы и композиции для ослабления иммунных ответов к пропускающему экзон вирусному трансферному вектору
DK3198017T3 (da) 2014-09-26 2021-04-12 Us Health Virusbaserede ekspressionsvektorer og anvendelser deraf
WO2019075360A1 (en) 2017-10-13 2019-04-18 Selecta Biosciences, Inc. METHODS AND COMPOSITIONS FOR MITIGATING ANTI-VECTOR VIRAL TRANSFER IGM RESPONSES
CA3141863A1 (en) 2019-05-28 2020-12-03 Selecta Biosciences, Inc. Methods and compositions for attenuated anti-viral transfer vector immune response
AU2021236089B2 (en) * 2020-03-13 2024-10-10 Nuo-Beta Pharmaceutical Technology (Shanghai) Co., Ltd. Anti-coronavirus effect and application of PI4K inhibitor
WO2021252557A1 (en) * 2020-06-09 2021-12-16 Alnylam Pharmaceuticals, Inc. Rnai compositions and methods of use thereof for delivery by inhalation
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
EP4527927A1 (en) * 2023-09-22 2025-03-26 Medizinische Hochschule Hannover Oligonucleotide-based strategies to combat respiratory viruses
WO2026063375A1 (ja) * 2024-09-20 2026-03-26 東亞合成株式会社 Ｒｓｖ ｐタンパク質 ｒｎａ配列に基づく新規二本鎖ｒｎａ及びその利用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) * 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US5693532A (en) * 1994-11-04 1997-12-02 Ribozyme Pharmaceuticals, Inc. Respiratory syncytial virus ribozymes
AU6848396A (en) * 1995-10-17 1997-05-07 Hybridon, Inc. Oligonucleotides with anti-respiratory syncytial virus activity
US6214805B1 (en) * 1996-02-15 2001-04-10 The United States Of America As Represented By The Department Of Health And Human Services RNase L activators and antisense oligonucleotides effective to treat RSV infections
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CN100523215C (zh) * 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
WO2002097114A2 (en) * 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
WO2003008628A2 (en) 2001-07-20 2003-01-30 Ribozyme Pharmacuticals, Inc. Enzymatic nucleic acid peptide conjugates
US20030203356A1 (en) * 2002-01-22 2003-10-30 The Cleveland Clinic Foundation RNase L activator-antisense complexes
US20030203868A1 (en) * 2002-02-06 2003-10-30 Bushman Frederic D. Inhibition of pathogen replication by RNA interference
AU2003299531A1 (en) * 2002-08-05 2004-06-07 University Of Massachusetts Compounds for modulating rna interference
EP1658304A4 (en) * 2002-09-28 2009-01-14 Massachusetts Inst Technology THERAPY ANTIGRIPPALE
US20040242518A1 (en) 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
WO2004042024A2 (en) * 2002-11-01 2004-05-21 The Trustees Of The University Of Pennsylvania COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF HIF-1 ALPHA
JP2007524349A (ja) * 2003-01-16 2007-08-30 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア ＩＣＡＭ−１のｓｉＲＮＡ阻害のための組成物及び方法
WO2004064737A2 (en) 2003-01-17 2004-08-05 Alnylam Pharmaceuticals Therapeutics compositions
CA2518475C (en) 2003-03-07 2014-12-23 Alnylam Pharmaceuticals, Inc. Irna agents comprising asymmetrical modifications
CA2522349A1 (en) 2003-04-17 2004-11-04 Alnylam Pharmaceuticals, Inc. Protected monomers
EP2669377A3 (en) 2003-04-17 2015-10-14 Alnylam Pharmaceuticals Inc. Modified iRNA agents
US20070238676A1 (en) * 2003-12-04 2007-10-11 Mohapatra Shyam S Polynucleotides for Reducing Respiratory Syncytial Virus Gene Expression
WO2006085987A2 (en) 2004-07-09 2006-08-17 University Of Iowa Research Foundation Rna interference in respiratory epitheial cells
EA017847B1 (ru) * 2005-01-07 2013-03-29 Элнилэм Фармасьютикалз, Инк. Композиция для лечения респираторных синцитиальных вирусов

Also Published As

Publication number Publication date
JP2008517940A (ja) 2008-05-29
EP1806968B1 (en) 2012-12-05
US7592322B2 (en) 2009-09-22
BRPI0517286A (pt) 2008-10-07
US20060089323A1 (en) 2006-04-27
WO2006062596A3 (en) 2007-05-18
MX2007004692A (es) 2007-09-07
EP1806968A2 (en) 2007-07-18
US20060089324A1 (en) 2006-04-27
CN101087527B (zh) 2012-01-18
EP1806968A4 (en) 2010-06-02
RU2494745C2 (ru) 2013-10-10
WO2006062596A2 (en) 2006-06-15
KR101193825B1 (ko) 2012-10-23
AU2005314617B2 (en) 2011-05-26
NO20071953L (no) 2007-05-18
CN101087527A (zh) 2007-12-12
AU2005314617A1 (en) 2006-06-15
KR20070106686A (ko) 2007-11-05
CA2584309A1 (en) 2006-06-15
RU2010139908A (ru) 2012-04-10
HK1114308A1 (en) 2008-10-31

Similar Documents

Publication Publication Date Title
KR101193825B1 (ko) ＲＳＶ, ＰＩＶ 및 기타 호흡기 바이러스의 ＲＮＡｉ 조절및 이의 용도
KR101169668B1 (ko) ＲＳＶ의 ＲＮＡｉ 조절 및 이를 위한 약제학적 조성물
US7790878B2 (en) RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
RU2409666C2 (ru) Модуляция rsv, piv и других респираторных вирусов с помощью rnai и ее применение
HK1114308B (en) Rnai modulation of rsv, piv and other respiratory viruses and uses thereof
NZ554494A (en) RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
HK1144102B (en) Rnai modulation of rsv and therapeutic uses thereof
HK1144102A1 (en) Rnai modulation of rsv and therapeutic uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20081008

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081008

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081008

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20081008

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20081008

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120206

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120306

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120330

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120703

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120704

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150713

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150713

Year of fee payment: 3

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D03

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150713

Year of fee payment: 3

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

LAPS Cancellation because of no payment of annual fees